Drug Profile


Alternative Names: AB-103; p 2 TA

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Atox Bio
  • Class Antibacterials; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Skin and soft tissue infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • Phase I Sepsis

Most Recent Events

  • 25 Sep 2017 Atox Bio receives the third tranche of a grant from the Biomedical Advanced Research and Development Authority for the development of reltecimod for Skin and soft tissue infections (Necrotising soft tissue infections)
  • 22 Jun 2017 Chemical structure information added
  • 15 Jun 2016 Atox Bio receives additional grant from US BARDA for the development of AB 103 for Necrotising soft tissue infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top